Menu
Presentation: Injectable solution in single-use vials for subcutaneous administration.
Dosage: Administered once weekly in a single dose, as prescribed by a physician.
Strength available in this presentation: 30mg/0.5mL.
Route of administration: Subcutaneous injection (abdomen, thigh, or upper arm).
Therapeutic class: Triple receptor agonist (GLP-1, GIP, Glucagon).
Expected benefits: Improved glycemic control, potential weight reduction, reduction of risks associated with type 2 diabetes.
Warnings: Prescription-only medicine. Keep out of reach of children.
Refrigerate at 2 °C to 8 °C (36 °F to 46 °F) in original carton, protected from light.
Do not freeze.
Retatrutide may be stored at room temperature (up to 30 °C / 86 °F) for a maximum of 21 days in the carton.
Discard if not used within 21 days after removal from the refrigerator.
Yes. While its primary indication is glycemic control in type 2 diabetes, Retatrutide may support weight management protocols. Always under medical prescription and supervision.
Retatrutide is administered once weekly by subcutaneous injection.
Retatrutide is available in vials of 10mg, 15mg, 30mg, 40mg, 50mg, and 60mg (all in 0.5mL single-use vials).
Yes. Retatrutide must be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original carton. It may remain at room temperature (up to 30°C / 86°F) for a maximum of 21 days.
The product is manufactured under strict international Good Manufacturing Practices (GMP) standards, ensuring purity, authenticity, and pharmaceutical quality.